09-05-2025
Korro Bio price target lowered to $53 from $130 at H.C. Wainwright
H.C. Wainwright lowered the firm's price target on Korro Bio (KRRO) to $53 from $130 and keeps a Buy rating on the shares. The company reported Q1 results and announced a 20% workforce reduction to extend its cash runway into 2027 from the second half of 2026, the analyst tells investors in a research note. The firm believes Korro's catalysts are on track but adjusted its model to reflect the 'increasingly competitive' alpha-1 antitrypsin deficiency landscape.
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today's best-performing stocks on TipRanks >>
Read More on KRRO:
Disclaimer & DisclosureReport an Issue
Korro Bio price target lowered to $100 from $115 at H.C. Wainwright
Strategic Workforce Restructuring and Clinical Advancements Justify Buy Rating for Korro Bio
Korro Bio reports Q1 EPS ($2.49), consensus ($2.62)
Korro Bio Announces Strategic Workforce Reduction Plan
Korro Bio initiated with an Overweight at Cantor Fitzgerald
